

---

## MEDIA RELEASE

---

### **Ypsomed streamlines executive management and expands European sales team**

Burgdorf, August 24<sup>th</sup>, 2010, 7:30am – In response to Ypsomed's increased strategic focus as a diabetes specialist company, Ypsomed is streamlining its executive management board in Switzerland and at the same time expanding its European sales organisation. Starting September 1<sup>st</sup>, 2010, the previous Chief Operating Officer (COO) Maurice Meytre is appointed as the new Chief Executive Officer (CEO) of Ypsotec AG (Grenchen), a subsidiary company of the Ypsomed group. At the same time, Dr. Christoph Rindlisbacher, previously Senior Vice President Corporate Development, will be leaving Ypsomed as of December 31<sup>st</sup>, 2010. Ypsomed is hereby reducing the executive management board to six persons and will further streamline its corporate structure in Switzerland. Maurice Meytre has substantially contributed to higher productivity and the consolidation of Ypsomed's manufacturing facilities. For nineteen years, Dr. Christoph Rindlisbacher was active in various management positions for both Ypsomed and Disetronic Group and in the past shaped the strategic direction of Ypsomed and the re-entering into the business of blood glucose monitoring systems as well as insulin infusion pumps. He will continue as Chief Executive Office (CEO) and trust member of the Ypsomed Innovation Fund. The board of directors would like to thank both gentlemen for their work on behalf of the Ypsomed Group and wishes both of them all the best in their future positions.

Richard Fritschi, CEO of the Ypsomed Group, comments: "The overwhelming interest and the huge demand in the market for the new mylife™ OmniPod® insulin patch pump exceeds our expectations. The insulin patch pump has no infusion set and offers patients with diabetes a greater degree of freedom and simplicity in use compared with conventional insulin pump therapy, while at the same time opening up new possibilities in the treatment of infants and young people. Consequently, Ypsomed will further expand its diabetes sales organisation in Europe over the coming months. At the same time we strive to continuously improve productivity in Switzerland and adapt the organisational structure as needed."

For further information, please contact Daniel Kusio, Head of Investor & Public Relations at Ypsomed Holding AG, on tel. +41 34 424 41 43 or tel. +41 34 424 41 11. This media release as well as other documents are available in electronic form from [www.ypsomed.com](http://www.ypsomed.com).

#### **About the Ypsomed Group**

The Ypsomed Group is a leading independent developer and manufacturer of injection systems for self-medication and a well-known diabetes specialist with more than 25 years' experience. Ypsomed is an innovation and technology leader with an extensive patent portfolio and is the preferred partner of pharmaceutical and biotech companies in the self-medication sector. The Ypsomed Group, which emerged in 2003 with at the time 550 employees from the well-known Disetronic Group, today employs approximately 1'200 employees. The Ypsomed Group has its headquarters in Burgdorf, Switzerland, and manufacturing sites in Burgdorf, Solothurn, Grenchen and the Czech Republic as well as leading independent diabetes product sales subsidiaries in Germany, France, Switzerland, the Netherlands, the Nordic countries as well as in India and since April 2010 in Great Britain.